ASCO 2024 - Dr. Jane Lowe Meisel Presents I-SPY2.2 Trial Results on Datopotamab Deruxtecan for High-Risk HER2-Negative Breast Cancer

Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.